Introduction {#sec1}
============

The pericardial fluid (PF) is an ultrafiltrate of plasma contained within the double-walled pericardial sac (also known as pericardium) that surrounds the heart and the roots of the great vessels (ascending aorta, superior and inferior vena cavae, pulmonary arteries and pulmonary veins) bringing blood to and from the heart cells (see [Figure S1](#mmc1){ref-type="supplementary-material"}).[@bib1] The pericardium is composed of two layers: (1) the superficial fibrous pericardium, composed of connective tissue, is continuous with the tunica adventitia of the great blood vessels and anchors the heart to the surrounding walls, and (2) the serous pericardium, composed of mesothelial cells. The serous pericardium is in turn formed by a parietal layer that fuses with the fibrous pericardium at the great vessels roots and the epicardium, which sits on and signals to the myocardium.[@bib2] Proteins introduced at the cavity surface of the endocardium can cross this layer, move between the myocardial cells, and accumulate under the epicardial mesothelium.[@bib3] Moreover, myocardial interstitial fluid can be drained from the subendocardium to the subepicardium via a network of intramyocardial lymphatic capillaries.[@bib4] Subsequently, molecules can be transported from the pericardial cavity to the peripheral circulation by the thoracic duct via the parietal pericardium, by the right lymphatic duct via the right pleural cavity,[@bib5] or through the capillary network and the venous system.[@bib6], [@bib7] Cardiac enzymes and troponins are present at higher levels in the PF than the peripheral blood, and increased levels of these molecules are used to aid the diagnosis of fatal myocardial infarct post-mortem.[@bib8], [@bib9] Additionally, the PF contains biologically active factors and components, of possible myocardial origin, including atrial and brain natriuretic peptides and endothelin-1.[@bib10] From the above, the myocardial contribution to PF content is apparent, and we reasoned that the PF composition might reflect, at least in part, the myocardium expression profile in health and disease.

MicroRNAs (miRNAs) are post-transcriptional inhibitors of gene expression, which act by provoking either the degradation or functional inhibition of their mRNA targets.[@bib11] The interaction between a miRNA and its targeted mRNAs happens within the RNA-induced silencing complex (RISC), which includes the Argonaute-2 (AGO-2) protein and the enzyme Dicer. Dicer also executes the final maturation step in miRNA biogenesis.[@bib11] miRNAs contribute to cardiovascular development, homeostasis, and disease.[@bib11] miRNAs can be released in biologically active forms by the parental cells, and they are stable in biological fluids, thus representing novel biomarker candidates.[@bib12] In fact, resilience of extracellular miRNAs is granted through different partnerships, such as with extracellular vesicles (EVs), lipoprotein complexes, and RNA-binding proteins or protein complexes, including AGO-2.[@bib11] Exosomes are the smallest (∼30--120 nm in size) of the known endogenous EVs. Exosomes have an endosomal origin and are retained within the multivesicular bodies (MVBs) as a result of endosome compartmentalization, being released when the latter fuse with the cell membrane.[@bib13] Exosomal miRNAs can be taken-up by non-parental cells, thus influencing their gene expression and ultimately working as cell-to-cell messengers in local and distant micro-communication mechanisms.[@bib11] The presence of miRNAs in the PF has been recently described.[@bib10] However, whether the PF miRNAs are of cardiac origin, if they are released via EVs, and their functional relevance have remained unaddressed.

Exosomes' molecular cargo is variable and dependent on the parental cell type and the environment. It is therefore intuitive that the actions of exosomes are disparate. Within the cardiovascular area, exosomes were reported to exert direct actions on cultured cardiac myocytes, including promoting hypertrophy[@bib14] and survival.[@bib15] Some pioneering human studies on circulating exosomes have focused at finding new clinical biomarkers, particularly in the oncology area, in which the concept of exosomes as "liquid biopsies" enriched with cancer cell-derived factors is receiving attention.[@bib16] However, the characterization of the exosomes present in human biological fluids and their possible role as cell-to-cell communicators of cardiovascular relevance is still undeveloped. We have recently provided preliminary evidence that exosomes containing high levels of cardiovascular miRNAs are trafficked out of the heart to reach the peripheral blood in patients undergoing cardiac surgery using cardiopulmonary bypass.[@bib17] This is an acute scenario that is associated with ischemia/reperfusion stress to the myocardium.[@bib17] Indeed, we observed that the abundance of plasma circulating exosomes and their content of cardiovascular miRNAs were highly correlated with high sensitive cardiac troponin T, the gold-standard biomarker of myocardial injury.[@bib17] This suggests that the release of exosomes from the heart is regulated in vivo. We reasoned that exosomes released by the heart and large vessels could accumulate in the pericardial space, which could gain new interest as a niche for cardiac biomarker discovery. Moreover, PF exosomes could be involved in yet unreported EV-based crosstalk between cells exposed directly or indirectly to the PF.

Results {#sec2}
=======

Human PF Is Enriched with miRNAs of Potential Cardiovascular Origin {#sec2.1}
-------------------------------------------------------------------

In search for evidence in support of our hypothesis that the PF is enriched with miRNAs released from the heart and thoracic vasculature, under ethical approval, we obtained the PF, peripheral blood-derived plasma, and leftover tissue samples of myocardium (right atrial appendage) and vasculature (ascending thoracic aorta) from surgical patients undergoing aortic valve replacement (AVR) (for study population, see [Table S1](#mmc1){ref-type="supplementary-material"}). An exploratory PCR-based miRNA microarray (Exiqon) on non-pooled, randomly selected samples of whole PF (n = 3) revealed the presence of several miRNAs in the PF of the patients (see [Table S2](#mmc1){ref-type="supplementary-material"}). Interestingly, several miRNAs of putative cardiovascular origin appear to be relatively highly expressed (see red text in [Table S2](#mmc1){ref-type="supplementary-material"}). Fifteen of these miRNAs were rationally selected for further analyses, together with miR-208 (supposedly enriched in cardiomyocytes) and the liver-enriched miR-122 (used as a "non-cardiovascular" control) (see [Table S3](#mmc1){ref-type="supplementary-material"} for the 16 cardiovascular miRNAs that were selected for further investigation and reporting the miRNA particulars). Working on surgical leftover samples, we validated that the 16 bona fide cardiovascular miRNAs were indeed well expressed in the myocardium and/or vasculature of the patients. By contrast and as expected, miR-122 was poorly expressed in the tissue samples ([Figure S2](#mmc1){ref-type="supplementary-material"}). Next, by performing PCR for individual miRNAs on matched PF and plasma samples, we obtained evidence supporting the concept that the PF is enriched with miRNAs released from cardiovascular tissues ([Figure 1](#fig1){ref-type="fig"}; [Supporting Materials and Methods](#mmc1){ref-type="supplementary-material"}). These data align with our hypothesis that the PF represents a liquid compartment in which expressional information and executive command from the heart and thoracic vessels are released in the form of miRNAs.Figure 1Human PF Is Enriched with MicroRNAs of Potential Cardiovascular OriginThe expression of selected microRNAs (miRNAs) was measured (RT-qPCR) in paired PF (black column) and peripheral plasma (gray column) samples. The PF/plasma concentration ratios of individual miRNAs are plotted on the right side of the graphs. Exogenous spike-in cel-miR-39 was the normalizer. MiR-122-5p was used as a non-cardiovascular control. N.D., not detectable. All values are mean + SEM. \*p ≤ 0.05, \*\*p ≤ 0.01, and \*\*\*p ≤ 0.001 versus plasma (unpaired Student's t test); n = 5--9.

Human PF Contains Exosomes Carrying Cardiovascular miRNAs {#sec2.2}
---------------------------------------------------------

We reasoned that the cardiovascular miRNAs present in the PF could, at least in part, be included in exosomal cargos. Nanosight LM10 nanoparticle tracking analyses (NTA) revealed the presence of exosome-sized (30--120 nm) particles in both the PF and plasma, which we analyzed as a reference ([Figures 2](#fig2){ref-type="fig"}A and 2B; the rectangles surround exosome-sized particles). Next, exosomes were enriched from the PF and plasma. The quality of the exosome preparations was validated by western blotting for a panel of exosomes antigens (ALIX, CD63, FLOT1, and EPCAM) ([Figure 2](#fig2){ref-type="fig"}C) and by transmission electron microscopy (TEM) using gold particles conjugated with an anti-CD63 antibody ([Figure 2](#fig2){ref-type="fig"}D) to confirm the exosome identity. The miRNAs already detected in the total PF where also measurable in the PF exosomes. Moreover, for the majority of the individual miRNAs, the expressional differences appreciated comparing whole PF versus whole plasma were confirmed when looking at the exosomal components of the two fluids ([Figure 3](#fig3){ref-type="fig"}A). This set of results suggests that miRNAs produced by cells of the heart and heart vessels are, at least in part, transported to the PF via exosomes. Next, to investigate if the miRNAs are differently distributed between the exosomal and non-exosomal fractions of the PF, we calculated the PF exosome/whole PF concentration ratios of the individual miRNAs. The PF exosome/total PF ratios were highly variable between miRNAs ([Figure 3](#fig3){ref-type="fig"}B), thus suggesting (1) a non-random incorporation of the miRNAs in the PF exosomes and/or (2) that miRNAs are released by cells via different mechanisms.Figure 2PF Contains Nanoparticles of the Size and Antigenic Profile of Exosomes(A and B) Nanoparticle tracking analysis (NTA) was used to quantify the concentration (A) and size distribution (B) of particles in the total PF and plasma. The dotted rectangles evidence exosome-sized vesicles (30--120 nm). (C and D) PF and plasma exosome preparations were positive for the exosomal markers ALIX, FLOT1, EpCAM and CD63. Transmission electron microscopy (TEM) using a gold particle-conjugated anti-CD63 antibody further confirmed exosome identity. In the bottom right corner of (D), next to CD63-immunoreactive exosomes, is shown a larger unreactive cytoplasmic vesicle as negative control (the scale bar represents 100 nm). Unpaired two-tailed Student's t test was applied. All values are mean + SEM; n = 5.Figure 3Human PF Exosomes Carry Cardiovascular miRNAs(A) miRNA level normalized to the spike-in cel-miR-39. (B) PF exosome/total PF ratios calculated for each miRNA. All values are mean + SEM. \*p ≤ 0.05, \*\*p ≤ 0.01, and \*\*\*p ≤ 0.001 versus plasma (unpaired Student's t test); n = 5.

PF Exosomes Contain the RISC Components AGO-2 and DICER {#sec2.3}
-------------------------------------------------------

To establish if AGO-2-miRNA complexes were present in the PF samples, AGO-2 immunoprecipitation (IP) was performed ([Figure 4](#fig4){ref-type="fig"}A) and followed by miRNA RT-qPCR analyses. The majority of our miRNAs were found conjugated to AGO-2 ([Figure 4](#fig4){ref-type="fig"}B). The relative expression of the individual miRNAs conjugated to AGO-2 was variable ([Figure 4](#fig4){ref-type="fig"}B), and it did not follow the same trends of exosomal miRNA expression ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, the majority of studied miRNAs were co-expressed in exosomes and AGO-2 complexes, suggesting the possibility that PF exosomes contain AGO-miRNA complexes. In line with this, AGO-2 was detected (by western blot analysis) in the PF exosome preparations ([Figure 4](#fig4){ref-type="fig"}C). Moreover, AGO-2-IP of PF exosomes, followed by PCR for a randomly selected subset of the miRNAs expressed in the AGO2 complexes, confirmed the presence of AGO-2-miRNA complexes in the exosomal compartment of human PF ([Figure 4](#fig4){ref-type="fig"}D). Also in this case, the relative expression of the individual exosomal miRNAs conjugated to AGO-2 was variable, with let-7b-5b appearing particularly enriched in the AGO-2 complex ([Figure 4](#fig4){ref-type="fig"}D). Dicer was also present within the PF exosomes ([Figure 4](#fig4){ref-type="fig"}E). Similarly to PF, plasma exosomes also contained both Dicer and AGO-2 ([Supporting Materials and Methods](#mmc1){ref-type="supplementary-material"}). When the exosome membrane was not previously destroyed by sonication, the exosomal miRNAs (let-7b-5p and miR-122) and proteins (DICER and AGO2) were resistant to proteinase K (PK) and RNase A digestion ([Figure S3](#mmc1){ref-type="supplementary-material"}). This favors the hypothesis that the miRNAs, DICER and AGO-2 were indeed encapsulated inside the exosomes, rather than being merely co-precipitated with them. Taken together, the above data provide evidence that exosomes contain miRNAs that are co-expressed and possibly physically associated with the RISC. It is therefore possible that exosomes deliver miRNAs together with a RISC machinery ready to act in recipient cells, thus immediately eliciting expressional changes commanding functional responses.Figure 4PF Exosomes Contain DICER and AGO-2 Protein(A) Validation by immunoblotting of AGO-2 immunoprecipitation (IP) performed on human PF samples using AGO-2 antibody. Mouse non-specific IgG antibody was used as control for the IP. ECs were used as positive control (CTRL). (B) The miRNA expression after AGO-2 IP is presented as fold enrichment relative to IgG; mean + SEM; n = 5. (C) AGO-2 in exosomes enriched from PF samples (representative western blot images). (D) AGO-2 IP was performed on exosomes enriched from PF samples. miRNA expression is expressed as fold enrichment in the AGO-2 IP relative to IgG; mean + SEM; n = 2. (E) Representative western blot images of DICER protein incorporated in the exosomes.

PF Exosomes Are Incorporated by Cultured ECs and Enhance Their Angiogenic Capacity {#sec2.4}
----------------------------------------------------------------------------------

To investigate whether the PF exosomes are functionally active, we tested them on cultured ECs focusing on responses that are conducive to angiogenesis. Patient-derived plasma exosomes were used for comparison. PF or plasma exosomes clusters, labeled with a green fluorescent marker, were added to cultured ECs, and their internalization was confirmed by confocal microscopy 3D and reconstruction of the confocal image z stacks ([Figures 5](#fig5){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}A). Two negative controls were included to confirm the specificity of the exosome uptake derived from the PF ([Figure S4](#mmc1){ref-type="supplementary-material"}). Next, exosomes were studied in cell biology assays developed on cells kept under hypoxia. In comparison to the PBS control, PF-derived exosomes inhibited EC apoptosis ([Figure 5](#fig5){ref-type="fig"}B) and increased EC proliferation ([Figure 5](#fig5){ref-type="fig"}C). Moreover, the PF exosomes, in comparison to PBS control and PF-derived exosomes, were also able to promote the formation of capillary-like cellular networks on Matrigel ([Figures 5](#fig5){ref-type="fig"}D, 5E, and [S5](#mmc1){ref-type="supplementary-material"}), while the exosome-depleted PF fraction had no effect. Plasma exosomes did not affect any of the tested EC functions ([Figures S6](#mmc1){ref-type="supplementary-material"}B--S6E). Exosome concentration-response curves confirmed the inactivity of plasma exosomes on ECs ([Figures S6](#mmc1){ref-type="supplementary-material"}F and S6G) in the concentration range whereas PF exosomes increased EC survival and proliferation ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I). We speculate that the differential behavior of exosomes from PF and plasma might be in part related to differences in their miRNA cargos.Figure 5PF-Derived Exosomes Are Incorporated by Cultured ECs and Enhance Their Angiogenic Capacity(A) PF-derived exosomes (10 μg/ml) stained using carboxyfluorescein succinimidyl ester (CFSE, in green) were incubated with ECs for 24 hr. Next, cells were stained with phalloidin (red) and DAPI (blue) (the scale bar represents 25 μm). (B and C) Column graphs show (B) EC apoptosis (measured by caspase-3 activity assay) and (C) EC proliferation (measured by BrdU incorporation) after treatment with 10 μg/ml of either PF- exosomes (black columns) or exosome-depleted PF (gray columns). PBS was used as an additional control (open columns); n = 7. (D) Photomicrographs show endothelial network formation on Matrigel (the scale bar represents 200 μm); 2.5× magnification. (E) Bar graphs show Matrigel assay quantification (total length of EC tube-like structures). All values are mean + SEM. \*p ≤ 0.05 and \*\*\*p ≤ 0.001 versus PBS, ^\#\ \#\ \#^p ≤ 0.001 versus PF exosome-free (one-way ANOVA, Dunnett's post hoc test); n = 6.

The PF-Enriched let-7b-5p Is a Proangiogenic miRNA {#sec2.5}
--------------------------------------------------

Next, we questioned whether exosomal miRNAs contributed to the angiogenic responses elicited by the PF exosomes. To answer this, we focused on let-7b-5p, which was chosen because it was highly expressed in the PF exosomes ([Figure 3](#fig3){ref-type="fig"}A), including as conjugated with AGO-2 ([Figure 4](#fig4){ref-type="fig"}D), and because other members of the Let-7 family were known to stimulate angiogenesis.[@bib18], [@bib19] Expressional data were validated using standard curves. In fact, we found that in comparison with plasma, the whole PF contained higher let-7b-5p and lower miR-122 copy numbers ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). Moreover, we confirmed the presence of let-7b-5p in PF exosomes ([Figure S7](#mmc1){ref-type="supplementary-material"}C). By transfecting ECs with a let-7b-5p mimic, a let-7b-5p inhibitor, or their respective controls (see [Figure 6](#fig6){ref-type="fig"}A for validation of the impact of transfection on let-7b-5p in ECs), we demonstrated that let-7b-5p promotes angiogenesis in vitro. In fact, increased let-7b-5p improved capillary-like tube formation on Matrigel ([Figure 6](#fig6){ref-type="fig"}B, top), while let-7b-5p inhibition produced the opposite effect ([Figure 6](#fig6){ref-type="fig"}B, bottom), and decreased EC proliferation ([Figure 6](#fig6){ref-type="fig"}D, right). By contrast, let-7b-5p did not affect the survival of cultured ECs ([Figure 6](#fig6){ref-type="fig"}C). We also determined whether the expression of three previously validated direct target genes of let-7b-5p was affected by forcing let-7b-5p expressional changes in ECs. Increased let-7b-5p reduced the mRNA expression of the antiangiogenic *TGFBR1* only[@bib20], [@bib21] ([Figure 6](#fig6){ref-type="fig"}E), leaving unchanged the other two potential target genes, *LOX-1* and *CASPASE 3* ([Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). Therefore, the latter were not taken forward for further analyses.Figure 6The PF-Enriched let-7b-5p Is a Proangiogenic MicroRNA(A) ECs were transfected with either a let-7b-5p mimic (right) or a let-7b-5p inhibitor (left). The random sequence anti-miR miRNA inhibitor (scramble) was used as control. Efficiency of let-7b-5p transfection was assessed by qPCR using U6 as a normalizer. (B) Matrigel assay photomicrograph (the scale bar represents 100 μm) and quantification (total length of tube-like structures), 5× magnification. (C and D) Caspase activity (C) and BrdU incorporation (D) of ECs transfected as previously described. (E) Relative expression of the let-7b-5p direct target gene *TGFBR1* (measured by PCR using ubiquitin C \[UBC\] as normalizer). All values are mean + SEM. \*p ≤ 0.05, \*\*p ≤ 0.01, and \*\*\*p ≤ 0.001 versus the respective scramble control (unpaired Student's t test); n = 4.

The Angiogenic Action of PF Exosomes Is Partially Mediated by let-7b-5p {#sec2.6}
-----------------------------------------------------------------------

We next interrogated the possibility that let-7b-5p could be transferred from PF exosomes to ECs and the expressional and functional impact of exosomal let-7b-5p uptake by recipient ECs. For these experiments, we adopted a model in which the endogenous expression of miRNAs is reduced. It was previously reported that miRNA biogenesis, and hence intracellular miRNA levels, are decreased after *DICER* silencing in cultured ECs. Moreover, *DICER* knockdown (KD) reportedly impairs the angiogenic capacity of cultured ECs.[@bib22] We initially confirmed that *DICER* KD resulted in reduced DICER gene and protein expression ([Figures S9](#mmc1){ref-type="supplementary-material"}A and S9B) and impaired the angiogenic potential of ECs ([Figures S9](#mmc1){ref-type="supplementary-material"}C and S9D). Moreover, as expected, *DICER* KD reduced let-7b-5p expression ([Figure 7](#fig7){ref-type="fig"}A). Next, ECs with either *DICER* KD or a preserved *DICER* expression were stimulated with our PF exosomes. Treatment with PF exosomes restored intracellular let-7b-5p expression, which had been compromised by *DICER* KD ([Figure 7](#fig7){ref-type="fig"}A), thus supporting the hypothesis that this proangiogenic miRNA is transferred from the PF exosomes to the recipient ECs. In line with the hypothesis that the let-7b-5p delivered from PF exosomes into ECs is functionally active, ECs treated with PF exosomes responded with a decreased mRNA expression of the miRNA target gene *TGFBR1* ([Figure 7](#fig7){ref-type="fig"}B). In ECs with *DICER* KD, treatment with PF exosomes was additionally able to restore DICER expression at protein ([Figure S10](#mmc1){ref-type="supplementary-material"}A), but not mRNA, levels (data not shown). This, together with the aforementioned finding of DICER presence in the exosomes ([Figure 4](#fig4){ref-type="fig"}E), further suggests that PF exosomes pass on miRNAs and other components of the RISC machinery to recipient cells. Finally, and in line with their induced let-7b-5p and *TGFBR1* expressional changes, PF exosomes restored the angiogenic capacity of *DICER* KO-ECs ([Figures 7](#fig7){ref-type="fig"}C and 7D). To further investigate the transfer of PF exosomal let-7b-5p to ECs and its functional consequence, we preventively suppressed let-7b-5p inside the exosomes. The reduction of exosomal let-7b-5p in PF exosomes transfected with the miRNA inhibitor was confirmed by qPCR ([Figure S10](#mmc1){ref-type="supplementary-material"}B). Moreover, the PF let-7b-5p KD-exosomes could not (1) restore let-7b-5p levels ([Figure 7](#fig7){ref-type="fig"}A), (2) decrease *TGFBR1* expression ([Figure 7](#fig7){ref-type="fig"}B), or (3) improve angiogenesis ([Figures 7](#fig7){ref-type="fig"}C and 7D) in recipient *DICER*-KD ECs. Taken together, these data support the hypothesis that PF exosomes are functionally active and stimulate angiogenesis, at least in part, via the passage of the proangiogenic let-7b-5p to ECs.Figure 7Let-7b-5p Underpins the Angiogenic Action of PF ExosomesECs were transfected with either a sequence that exhibits no homology to the human genome (scramble) or *DICER* silencing RNA (siRNA) to knock down (KD) *DICER* for 24 hr, before being treated with either naive PF exosomes or PF exosomes previously depleted of their let-7b-5p content (exosome let-7b-5p KD). (A and B) Columns graphs show the relative expression of (A) let-7b-5p and (B) *TGFBR1* in the exosome recipient ECs and untreated cell controls; n = 4. (C) Photomicrographs (the scale bar represents 100 μm) and (D) quantification of Matrigel assays performed using ECs treated as previously indicated; n = 5; 2.5× magnification. All values are mean + SEM. ^§^p ≤ 0.05 and ^§§§^p ≤ 0.001 versus scramble, \*p ≤ 0.05 and \*\*\*p ≤ 0.001 versus *DICER* KD, ^\#^p ≤ 0.05 and ^\#\#^p ≤ 0.01 *DICER* KD treated with naive PF exosomes (one-way ANOVA, Tukey's post hoc test).

PF-Derived Exosomes Promote Post-ischemic Angiogenesis and Blood Flow Recovery {#sec2.7}
------------------------------------------------------------------------------

We investigated whether the angiogenic capacity shown by PF exosomes in vitro may translate into improvement of angiogenesis and blood flow recovery in vivo. The therapeutic potential of PF exosomes was studied in a mouse model of ischemia, in which local stimulation of angiogenesis represents a possibility to improve tissue perfusion. As controls, we used PBS and plasma exosomes, which we had proved unable to induce in vitro angiogenesis ([Figures S6](#mmc1){ref-type="supplementary-material"}B--S6G). Mice with surgically induced unilateral limb ischemia were injected with either PBS or exosomes (100 μg/mouse) directly into their ischemic adductor muscles. Compared with PBS, at 7 days from delivery, the PF-derived exosomes improved post-ischemic blood flow recovery ([Figures 8](#fig8){ref-type="fig"}A and 8B), reduced the incidence of ischemia-induced toe necrosis ([Figure 8](#fig8){ref-type="fig"}C), and improved capillary density in ischemic muscles ([Figures 8](#fig8){ref-type="fig"}D and 8E). The positive impact of PF exosomes on blood flow recovery was not sustained over time (data not shown). Plasma exosomes were not able to reproduce any of the above therapeutic benefits ([Figures 8](#fig8){ref-type="fig"}A--8E). Importantly, after transfer of PF exosomes into ischemic limb muscles, there was a trend toward increased let-7b-5p expression (p = 0.18; [Figure 8](#fig8){ref-type="fig"}F) and a significant decrease in *Tgfbr1* expression (p \< 0.05; [Figure 8](#fig8){ref-type="fig"}G), which could be explained by an amplified functional response at the target gene level of the PF exosome-mediated delivery of active let-7b-5p.Figure 8PF-Derived Exosomes Promote Reparative Angiogenesis and Blood Flow Recovery in a Mouse Limb Ischemia ModelUnilateral limb ischemia was surgically induced in CD1 mice. Next, mice were injected in their ischemic adductor muscle with 100 μg of exosomes from either the PF or plasma. A control group received PBS. (A) Representative color laser Doppler images of lower limb perfusion at baseline and at day 7 post-ischemia. (B) The blood flow recovery to the ischemic foot was calculated as percentage versus the contralateral foot (n = 20 mice/group). (C) Percentage of necrotic toes in animals treated with PBS, PF, or plasma-derived exosomes. \*\*p \< 0.01 versus PBS. (D) Representative immunofluorescent images of ischemic adductor muscle sections after staining with green fluorescent isolectin-B4. (E) Capillary densities in the ischemic adductors at 7 days post-ischemia induction (n = 8 per group). Average capillary density was determined from eight randomly selected high-power fields (magnification 20×). ^\#\#^p \< 0.01 versus PBS. (F and G) Let-7b-5p (F) and *Tgfbr1* (G) expression in ischemic mouse adductors injected with PF exosomes or PBS (control); n = 5. \*p ≤ 0.05 versus PBS. All values are mean + SEM.

In conclusion, the exosomes contained in human PF have shown the capacity to induce vascular protective and reparative functions in vitro and in vivo, suggesting their importance in the context of cardiovascular physiopathology.

Discussion {#sec3}
==========

Vascular cells, cardiomyocytes, cardiac fibroblasts, and cardiac progenitor cells reportedly secrete miRNA-containing exosomes in culture systems.[@bib23] Functional studies focusing on exosomes in human biological fluids are still lacking. Such studies are of importance to characterize the relevance of exosome-based communication in human pathophysiology. We have reported the vascular regenerative potential of exosomes prepared from biological fluids collected from cardiovascular patients.

Exosomes produced from stem and progenitor cells, including the ones isolated from cultured adult cardiac progenitor cells (CPCs), which have been claimed to reside in the human heart and contribute to myocardial regeneration, have shown proangiogenic effects.[@bib24], [@bib25] However, the in vivo abundance and physiological relevance of CPCs are currently intensively questioned,[@bib26], [@bib27] thus discouraging the speculation that exosomes released in vivo by CPCs play a major role in heart homeostasis. Stem and progenitor cells still represent hope for vascular regeneration. In a seminal paper, Sahoo et al.[@bib28] showed that bone marrow mononuclear cell (MNC)-derived CD34-positive cells promote therapeutic angiogenesis in vitro and in vivo via paracrine actions that can be recapitulated by their exosomes, but not by exosomes from MNCs. Later studies have expanded on this to recognize that proangiogenic exosomes are released in culture by the different types of progenitor cells so far trialled in patients with heart ischemia.[@bib13] These findings open new exciting therapeutic avenues but do not address the contribution of endogenous exosomes to cardiovascular physiopathology. Additionally, not all exosomes stimulate angiogenesis. As an example, exosomes from diabetic cardiomyocytes reportedly inhibited endothelial cell (EC) survival and angiogenesis by the transfer of miRNA-320.[@bib29]

The angiogenic response to PF exosomes described in our study appears "specific" to PF-derived exosomes because it could not be reproduced using exosomes prepared from the plasma of the same patients. Evidence from the literature suggests that peripheral plasma exosomes could elicit different cardioprotective functions.[@bib15] Alternatively, the type of patients we have studied could present with alterations in their plasma exosomes. This study was conducted on patients with aortic stenosis undergoing aortic valve replacement. These patients are afflicted by left ventricular hypertrophy. Cardiac hypertrophy is associated with complex multicellular alterations, including hypertrophy, fibrosis, and inflammation.[@bib30] These actions are brought about by cardiac and non-cardiac cells through a variety of cell-to-cell communication pathways.[@bib30] In particular, during cardiac hypertrophy, the contractile function of the myocardium must be sustained by phenotypic changes of the capillary ECs leading to angiogenesis. Previous studies identified that proangiogenic factors released by cardiac myocytes sustain the capillary density and the oxygen supply.[@bib31], [@bib32] Our data are in line with the new paradigm that PF exosomes and their miRNAs contribute to modulating the growth of new capillary vessels, thus protecting the heart from an accelerated failure. In support of this hypothesis, we found that the PF exosomes isolated from cardiovascular patients promote angiogenesis in vitro and in vivo. However, it is also possible that compared with healthy controls, PF exosomes from AVR patients have a reduced altered proangiogenic potential. This question could not be investigated in our human studies and will need to be deferred to work on suitable animal models.

We have mechanistically implicated a newly defined pro-angiogenic miRNA, let-7b-5p, in the proangiogenic responses to PF exosomes. However, in addition to let-7b-5p and other proangiogenic miRNAs, PF exosomes also contain several anti-angiogenic miRNAs ([Table S3](#mmc1){ref-type="supplementary-material"}). The overall proangiogenic responses to the PF exosomes might be dictated by a functional prevalence of proangiogenic miRNAs that are simultaneously transferred by the same nanoparticles. However we cannot discount the possibility that anti-angiogenic miRNAs are enriched in a subset of exosomes that are taken up with reduced efficiency by the ECs. Moreover, the expression of individual miRNAs in a cell context and possibly in the exosomes does not always reflect the level of the individual miRNAs binding to AGO-2 and hence their functionality. In fact, it is emerging that the association between miRNAs and the RISC complex is a regulated process. As an example, Krell et al.[@bib33] showed that following DNA damage, P53 interacts with AGO-2 to induce or reduce AGO-2's association with subsets of miRNAs, including multiple let-7 family members.

Our study provides the first evidence that the pericardial space might represent a special compartment, in which functional forms of miRNAs that are released from the heart are enriched in comparison with the peripheral circulation. Because of their resilience to degradation in the extracellular space, miRNAs have been widely considered as new potential clinical biomarkers. Pioneer miRNA-oriented biomarker discovery studies have been developed by measuring miRNAs in the peripheral circulation. However, the emerging evidence for the multi-cellular and multi-tissue expression of virtually any of the known miRNAs, together with the understanding that several processes (release from different cells and organs, potential uptake from the circulation into other tissues, urinary excretion, etc.) dictate the miRNA concentration in the peripheral blood, diminish the potential value of miRNAs as peripheral blood circulating biomarkers. We propose that miRNA expression in the PF is more indicative of cardiac miRNA expression and secretion. In defense of our hypothesis, we have shown increased cardiovascular miRNA expression in the total PF and in PF-derived exosomes in comparison with the corresponding plasma counterparts. Exosomes have been already suggested as "liquid biopsies."[@bib34] Our study stimulates the original hypothesis that obtaining such liquid biopsies out of the PF (when accessible) rather than from the peripheral blood could increase the diagnostic and prognostic power of exosomal biomarkers. Specifically designed clinical studies are necessary to validate the biomarker value of PF miRNAs.

In this study, we have used human exosomes in immunocompetent mice. It was already published that exosomes derived from human progenitor cells can induce therapeutic effects in immunocompetent small[@bib35] and large[@bib36] animal models. Nonetheless, we cannot discount the possibility that an immune response could have reduced the therapeutic efficacy of the exosomes. In line with this possibility, the positive impact of PF exosomes on blood flow recovery was not sustained over time. On the other hand, exosomes have been suggested to be able to modulate immunity.[@bib37] Given the increasingly recognized importance of the crosstalk between the immune and cardiovascular systems in health and disease, we would not exclude that exosomes could influence cardiovascular responses partly by modulating the immune system.

The interest in exosomes as new therapeutic tools is growing.[@bib28], [@bib38] The production of exosomes from patients' own cells and biological fluids could represent a new avenue for autologous regenerative therapies. Additionally, careful characterization of endogenous exosomes with proven therapeutic capacity should help with the future fabrication of nature-inspired artificial vesicles carrying a defined therapeutic cargo, which could represent an option for developing exosomes into off-the-shelf therapeutic products to be used in different cardiac and non-cardiac conditions.

Study Limitations {#sec3.1}
-----------------

First, we have conducted an exploratory study using anonymized surgical leftover material from patients undergoing AVR. As such, our study has been able to provide the first characterization of the PF exosomal compartment but not to investigate its biomarker value. Prospective studies collecting clinical samples and data (at baseline and follow-up) from surgical and non-surgical patients are next required. Interestingly, the PF represents a leftover material from most cardiac surgeries and is also sampled for diagnostic purposes in non-surgical patients.[@bib39], [@bib40] However, this fluid is not always accessible, thus limiting the translational potential to particular clinical conditions and to restricted time windows. Second, we have focused on the proangiogenic actions elicited by PF exosomes. We already know that PF exosomes are taken up by additional types of heart cells (C.B., unpublished data) and further studies will be necessary to disclose their full spectrum of actions. Third, we have concentrated our attention on miRNAs. However, other molecular components of the exosome cargo could contribute to the angiogenic effects of exosomes as well as representing potential biomarkers. Fourth, and conversely, extracellular miRNAs are not only contained in exosomes, and the fundamental and translational importance of miRNAs carried via different transporter systems is not to be neglected.

Materials and Methods {#sec4}
=====================

Clinical Sample Collection and Processing {#sec4.1}
-----------------------------------------

The collection and use of clinical samples for research complied with the ethical principles stated in the "Declaration of Helsinki" and the Human Tissue Act and were covered by ethical approvals from the UK National Research Ethic Service NRES (Research Ethic Committee --REC- references 13/OL/1687 and 10/HO107/63). We collected leftover samples from patients undergoing aortic valve replacement (AVR). The total PF volume was collected immediately after opening of the pericardium using a 20 mL syringe and transported to the laboratory in a sterile 50 mL container. Peripheral blood was collected from an arterial line in citrate-containing vacutainers (BD). Samples of right atrial appendage (RAA) were collected just before cannulation of the right atrium, and samples of ascending thoracic aorta were collected from excessive tissue on closure of the aortotomy. These were immediately placed in RNA Later stabilizing solution (Thermo Fisher Scientific) and stored at −80°C until processed. Blood and PF were processed immediately after collection, as follows. To obtain plasma, the citrate-containing vacutainers were centrifuged at 1,500 × *g*, 4°C for 15 min, and the supernatant was collected. The supernatant underwent further centrifugation at 13,500 × *g*, room temperature (RT), for 5 min to deplete the sample of miRNA-rich platelets. The platelet-free fluid was centrifuged at 13,500 × *g*, RT, for 5 min to remove any remaining of cells. The final platelet-poor plasma, PF and tissue samples were stored at −80°C until required.

RNA Extraction and Quantitative Real-Time Analysis {#sec4.2}
--------------------------------------------------

Total RNA was extracted using the miRNeasy kit (Qiagen), according to the manufacturer's instructions. For RNA extraction from solid tissues (ascending thoracic aorta and right atrial appendage), about 50 mg of tissue was first homogenized in 1 mL QIAzol (Qiagen) in a gentleMACS M tube using the gentleMACS dissociator (both from Miltenyi Biotec). For RNA extraction from PF and plasma, 200 μl of sample was used with 1 mL of QIAzol. A synthetic analog of the non-human *Caenorhabditis elegans* microRNA-39 (cel-miRNA-39; Qiagen) was spiked in (10 μl of a 5 fmol/μl stock) to normalize RNA extraction efficiency. Reverse transcription of individual miRNAs was performed using the TaqMan miRNA Reverse Transcription Kit and miRNA-specific stem-loop primers (see [Table S3](#mmc1){ref-type="supplementary-material"}; Thermo Fisher Scientific). qPCR was performed in triplicate using 2x Universal PCR Master Mix with No AmpErase UNG (Thermo Fisher Scientific) using the QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific). miRNA expression was normalized with either cel-miRNA-39 (for biological fluids) or with the small nuclear U6 small nuclear RNA (snRNA) (ID: 001973) (for solid tissues). For mRNA analysis, cDNA obtained using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific) was amplified by real-time qPCR. TaqMan Gene Expression Assays (Thermo Fisher Scientific) and 2x Universal PCR Master Mix with No AmpErase UNG (Thermo Fisher Scientific) were used to analyze the gene expression of TGFBR1 (ID: Hs00610320_m1), CASPASE3 (ID: Hs00234387_m1), LOX (ID: Hs00942480_m1), and UBC (ID: Hs00824723_m1) (all from Thermo Fisher Scientific). Real-time quantification to measure gene expression for human DICER and mouse TGFBR1 was performed using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific) and normalized against human or mouse GAPDH.

Primers used were as follows:Human DICER Fw: ATTCTAGTGCAGGTTTTTCAAGCC,Human DICER Rv: ACCTCAGATTCCACACTTTCCTG,Human GAPDH Fw: AGCCGCATCTTCTTTTGCGT,Human GAPDH Rv: TGACGAACATGGGGCATCA,Mouse TGFBR1 Fw: AGAGCTGTGAGGCCTTGAGAMouse TGFBR1 Rv: TTGATGCCTTCCTGTTGGCTMouse GAPDH Fw: TGTGAACGGATTTGGCCGTAMouse GAPDH Rv: ACTGTGCCGTTGAATTTGCC.

For absolute miRNA quantification, the Ct value obtained from a dilution series (ranging from 100 nM down to 10 fM) of chemically synthesized RNA oligonucleotides corresponding to the mature miRNA sequence of let-7b-5p (UGAGGUAGUAGGUUGUGUGGUU) and miRNA-122-5p (UGGAGUGUGACAAUGGUGUUUG) were used to generate standard curves (both were purchased from Sigma).

miRNA Array on Human Pericardial Fluid {#sec4.3}
--------------------------------------

Total RNA was converted to cDNA using a reverse transcription kit (Universal cDNA Synthesis Kit, Exiqon). Three (unpooled) PF samples of the AVR surgical patient group were randomly selected to be run in a PCR-based miRNA array enabling the profiling of 752 human miRNAs (miRNACURY LNA microRNA PCR human panels I and II; version 3, Exiqon). The miRNA array plates were run using a LightCycler 480 (Roche).

miRNA Array Bioinformatics Analyses {#sec4.4}
-----------------------------------

For the bioinformatics analyses, the processing settings were as follows: (1) detection scoring: miRNAs not detectable in all three samples or Ct ≥ 37 in at least two patients were not considered for future calculations; (2) the average of inter-plate calibrator (UniSp3 IPC) was calculated for each run (representing one sample), and the median was subtracted from each miRNA's Ct; and (3) expression of each miRNA was derived using the 2^−ΔΔCT^ method.[@bib41] On the basis of these criteria, array data were inspected using the NormFinder algorithm to assess the variance in expression levels.[@bib42] The best normalizer was found to be the average of assays detected in all three AVR samples; therefore this was used to normalize the array. Data are available at Gene Expression Omnibus (GEO: [GSE80577](ncbi-geo:GSE80577){#intref0010}).

PF and Plasma Nanoparticle Profiling {#sec4.5}
------------------------------------

EVs present in whole plasma or PF were characterized using Nanoparticle Tracking Analysis (NTA). One microliter of sample was diluted in sterile water to obtain a suitable concentration to be read, according to the manufacturer's guidelines. The sample was passed through the flow cell. Once the temperature of the flow cell had stabilized at 25°C, six 30 s videos of each sample were taken with a high-resolution camera, with a 1 s pause between each. The videos were then processed by Nanoparticle Tracking Analysis software (version 2.3), giving the concentration of particles per ml for each nanometer size. The final data for each sample is an average of the data from six videos.

Exosome Enrichment from the PF and Plasma {#sec4.6}
-----------------------------------------

Exosomes were enriched from 250 μl of PF and plasma using the ExoQuick kit (System Biosciences). Thrombin (2.5 μl) (500 U/mL, System Biosciences) per 250 μl plasma was added to remove the fibrin proteins. The samples were incubated at RT for 15 min while mixing, then centrifuged at 10,000 × *g* for 5 min at RT. PF and fibrin-depleted plasma were then filtered through a sterile 0.22 μm filter (Merck Millipore) into a fresh tube, and 75 μl ExoQuick solution was added. The samples were incubated for 30 min at 4°C, then centrifuged for 30 min at 1,500 × *g* and 4°C. The supernatant was removed, and following an additional centrifugation of the sample at 1,500 × *g* for 5 min at 4°C, the fluid was taken off and the pellet was re-suspended in 100 μl of sterile PBS. At the end of the process, the presence of exosomes in the preparation was confirmed by NTA, electron microscopy (see below) and western blotting. Protein concentrations were determined using Micro BCA protein assay (Thermo Fisher Scientific), and specified exosome doses used in experiments are based on these. miRNAs from exosomes were isolated using the miRNAeasy kit (Qiagen) (see above).

Treatment of Exosomes with Proteinase K and RNase A {#sec4.7}
---------------------------------------------------

For this assay, exosomes obtained according to our method (see above) were treated as previously described.[@bib43] Isolated exosomes were incubated with proteinase K (50 μg/ml; Sigma) for 10 min at 37°C, before 5 mM phenulmethulsulfonyl fluoride (PMSF; Sigma) was added for 10 min at room temperature to inhibit the proteinase K (PK) activity. After the PK inactivation, the samples were incubated with 100 μg/ml RNase A (Thermo Fisher Scientific) for 20 min at 37°C to degrade unprotected RNA, followed by incubation with RiboLock RNase Inhibitor (Thermo Fisher Scientific). Finally protein or RNA was extracted as described earlier. As control samples we included (1) sonicated exosomes followed by treatment with PK and RNase A or (2) exosomes treated with PBS added instead of PK and RNase A.

Electron Microscopy {#sec4.8}
-------------------

For morphological studies, each formvar-coated grid was positioned on top of a 5 μl droplet of the pellet containing exosomes, previously fixed for two hours at 4°C in Karnovsky fixative (2% formaldehyde + 2% glutaraldehyde) for 60 min. Afterward, the grid was sequentially positioned on three drops of 0.05 M, pH 7.3 cacodylate buffer for 5 min each. For ultrastructural immunocytochemical study, each formvar-coated grid was positioned on the top of a 5 μl drop of the pellet containing exosomes previously fixed for 2 hr at 4°C in modified Karnovsky fixative (2% formaldehyde + 0.5% glutaraldehyde) for 60 min. The grid was then put on three drops of 0.05 M, pH 7.3 cacodylate buffer for 5 min each, on 2% formaldehyde for 10 min, on three drops of 0.05 M, pH 7.3 cacodylate buffer for 5 min each, on the antibody anti-CD63 (ab23792; Abcam) diluted 1:20 for 60 min, on three drops of 1% BSA in 0.05 M, pH 7.4 Tris buffered saline buffer for 5 min each, on the gold-tagged anti-mouse antibody (Jackson Immunoresearch) diluted 1:20 for 60 min, and on three drops of 0.05 M, pH 7.4 Tris buffered saline buffer for 5 min each. Next, both for morphological and for immunocytochemical study, the grids were placed on a drop of 2% glutaraldehyde for 10 min, then on three drops of distilled water for 5 min each, on 5% uranyl acetate for 3 min, and finally on 0.013% methyl cellulose/0.04% uranyl acetate for 10 min on ice (Lasser). Between each transfer, the excess liquid was removed by holding an absorbing paper close to the side of the grid.

PF Exosome Incorporation by ECs {#sec4.9}
-------------------------------

PF-derived exosomes were labeled using Exo-Glow based on carboxyfluorescein succinimidyl diacetate ester (CFSE) chemistry (System Biosciences) according to the manufacturer's recommendations. Human umbilical vein ECs (HUVECs) (Lonza) were seeded at a density of 5 × 10^4^ cells/well on a 24-well plate coverslip, and 10 μg/ml of labeled PF-derived exosomes were added to target ECs in culture for 24 hr at 37°C. Cells were washed twice with PBS and fixed with 4% buffered PFA (Sigma) in PBS for 20 min at RT. Nuclei were stained by DAPI staining while actin filaments were labeled using Rhodamine Phalloidin (Thermo Fisher Scientific). To assess the uptake of exosomes by ECs, confocal images were acquired with a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 inverted epifluorescence microscope. All images were collected using a 63× NA 1.4 oil immersion lens objective. The excitation signals for Exo-Glow and Rhodamine Phalloidin were 494 and 540 nm, respectively. The fluorescence emitted from the cells was recorded at 521 nm for Exo-Glow and 565 nm for Rhodamine Phalloidin. In all cases, z-stack images were obtained covering the entire cell volume. Three-dimensional reconstruction of the confocal image z stacks confirmed the cytoplasmatic localization of internalized exosomes.

Cell Culture and Cell Biology {#sec4.10}
-----------------------------

HUVECs (Lonza) were grown in endothelial cell basal medium, EBM-2 (Lonza), with the addition of 2% FBS and SingleQuots Kit (EGM-2 medium; Lonza) at 37°C with 5% CO~2~. After the first expansion, cells were then grown in EGM-2 medium using 2% exosome-depleted FBS (System Biosciences). To mimic ischemia in vitro, ECs were exposed to hypoxia (1% pO~2~) for 24 hr followed by treatment with different concentrations of PF/plasma-derived exosomes or exosome-depleted PF/plasma for 24 hr. HUVECs were used between passages 2 and 6.

Evaluation of Apoptosis and BrdU Incorporation in ECs {#sec4.11}
-----------------------------------------------------

HUVECs were seeded in 96-well plates (5 × 10^3^/well) and treated with 5, 10, or 20 μg/ml of PF exosomes or the same concentrations of exosome-depleted PF for 24 hr in hypoxia (1% pO~2~). The medium was then replaced with a complete medium with supplemental BrdU (10 μM) for 24 hr. BrdU incorporation was measured using the BrdU ELISA assay kit (Roche). Caspase-3/7 activity was measured at 24 hr using a luminescent cell death detection kit according to the manufacturer's instructions (Caspase-GLO assay; Promega).

In Vitro Angiogenesis {#sec4.12}
---------------------

HUVECs were seeded in 6-well plates (2 × 10^5^/well) and treated with 10 μg/ml of PF/plasma exosomes or exosome-depleted PF/plasma for 24 hr in hypoxia, then detached using Accutase (Innovative Cell Technologies) and plated (10^4^/well) in a flat-bottom 96-well plate or μ-Slide Angiogenesis (Ibidi), coated with Growth Factor Reduced Matrigel (Corning). For *mir*Vana miRNA mimic or *mir*Vana miRNA inhibitor experiments, HUVECs were seeded at a concentration of 7 × 10^3^/well. After 6 hr, HUVECs were stained with Calcein AM (Biotium), and network formation was quantified by calculating the length of the cellular network on images captured using an objective magnification of 5× or by Angiogenesis Analyzer for ImageJ using a fluorescence objective magnification of 2.5×.

HUVEC and Exosome Transfection {#sec4.13}
------------------------------

Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used to transfect HUVECs with scramble siRNA (75 nM total), siRNAs against DICER (25 nM for each siRNA, 75 nM total), *mir*Vana miRNA mimic let-7b-5p (12.5 nM, MC11050), and *mir*Vana miRNA inhibitor let-7b-5p (12.5 nM, MH11050), Pre-miR Negative Control (12.5 nM, AM17120) and Anti-miR Negative Control (12.5 nM, AM17011) (all from Thermo Fisher Scientific), according to the manufacturer's instructions. Published sequences[@bib22], [@bib44] of siRNA against DICER and scramble were used (all purchased from Qiagen).

Exosomes were transfected with *mir*Vana miRNA inhibitor let-7b-5p (MH11050; Thermo Fisher Scientific) using Exo-Fect Exosome Transfection Kit (System Biosciences) and following the guideline's recommendations.

In Vivo Experiments {#sec4.14}
-------------------

The experiments involving mice were performed in accordance with the Animal (Scientific Procedures) Act (UK) of 1986 prepared by the Institute of Laboratory Animal Resources and under the auspices of UK Home Office Project and personal licenses. Eight-week-old CD1 male mice underwent surgical induction of unilateral limb ischemia (LI) by performing occlusion of the left femoral artery, as we reported previously.[@bib45] Immediately after LI induction, mice received 100 μg of exosomes derived from either PF or plasma into the ischemic adductor muscle, while a control group received PBS (n = 20 mice/group). The superficial blood flow to both ischemic and non-ischemic feet was measured using a high-resolution laser color Doppler imaging system (Moor LDI2, Moor Instruments) at days 0 and 7 after induction of limb ischemia. Blood flow recovery was calculated as a percentage versus day 0 of the control PBS. At day 7, mice under terminal anesthesia were perfusion-fixed successively with 6 mL of 0.05 M EDTA and 10 mL of 10% formalin solution. Limb muscles were harvested and stored in PFA 4% overnight at room temperature then washed with PBS and finally treated with 30% sucrose overnight at 4°C. The tissue samples were then embedded in optical cutting temperature (OCT) compound and stored at −80°C until histological and immunohistochemical analyses. A second set of mice (n = 12 per group) were made ischemic and immediately treated with either PF exosomes or PBS as described above. Doppler analyses were performed at baseline, 7, 14, and 21 days post-ischemia induction. For molecular biology analyses, mice were sacrificed at 3 days after surgery, and the ischemic abductor muscles were dissected and snap-frozen in liquid nitrogen. Total RNA was extracted from snap-frozen muscles as described above.

Histology {#sec4.15}
---------

The experiments involving mice were performed in accordance with the Animal (Scientific Procedures) Act (UK) 1986 prepared by the Institute of Laboratory Animal Resources and covered under the UK Home Office Project license PPL/30/3373. The functional impact of PF- and plasma-derived exosomes on treatment of CD1-ischemic mice was assessed by measuring capillary density in the adductor muscle. Eight-micrometer-thick muscle sections were stained using biotin-conjugated Isolectin B4 (from Griffonia Simplicifolia; Thermo Fisher Scientific) and streptavidin-conjugated Alexa 488 (Thermo Fisher Scientific) antibodies to detect capillaries. Nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole). The slides were mounted using Fluoromount-G (eBioscience). The relative number of positive cells was counted in eight randomly selected high-power fields (magnification 20×) using a Zeiss inverted fluorescence microscope. Analyses were performed using muscles from eight mice per group. Capillary density was expressed as number per square millimeter.

Immunoprecipitation and Western Blot Analysis {#sec4.16}
---------------------------------------------

One hundred microliters of Magna Bind goat anti-mouse IgG Magnetic Beads (Thermo Fisher Scientific) were washed three times with PBS solution (200 μl) and incubated with 10 μg of mouse monoclonal anti-AGO2 (ab57113, Abcam) or mouse IgG (Santa Cruz Biotechnology) antibodies for 2 hr at 4°C. The pre-incubated beads and antibodies were then added to 200 μL of PF and incubated overnight at 4°C. Beads were washed 3 times with 1% Nonidet P-40 buffer and re-suspended in 200 μL of PBS. One half of each sample was eluted in loading buffer followed by western blot analysis. Protein extracted from HUVECs was used as a positive control. The other half was eluted in 750 μL of QIAzol and processed for RNA isolation and miRNA detection (see above). Exosomes and cells were lysed with RIPA buffer (Santa Cruz Biotechnology) with an added protease inhibitor cocktail. Samples were centrifuged at 14,000 × *g* for 15 min at 4°C, and the supernatant fractions were used for western blot. Western blot was performed as previously described.[@bib46] The following antibodies were used: Alix (Millipore, ABC40; 1:1,000; Merk Millipore), Flotillin-1 (BD, 610820, 1:1,000), EPCAM (Cell Signaling Technology, 2626; 1:1,000), CD63 (Abcam, ab59479; 1:1,000), AGO2 (Abcam, ab57113; 1:1,000), DICER (Abcam, ab14601, 1:500), β-Actin (Sigma, A5441; 1:50,000), ECL Mouse IgG (GE Healthcare, NA931; 1:2,000), and ECL Rabbit IgG (GE Healthcare, NA934; 1:2,000).

Statistical Analysis {#sec4.17}
--------------------

Comparisons between two different conditions were assessed using the two-tailed Student's t test. If the normality test failed, the Mann-Whitney test was performed. Experiments with three or more experimental groups were compared using one-way ANOVA with either a post hoc Dunnett's or Tukey's multi-comparison test, as appropriate. Toe survival was tested using log rank analysis. The data are expressed as mean ± SEM. p values less than 0.05 were considered to indicate statistical significance (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p ≤ 0.001). Analyses were performed using Prism software version 6 (Graph Pad).
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